Connor, Clark & Lunn Investment Management Ltd. Chinook Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$21.53 - $26.8 $1.41 Million - $1.76 Million	-65,605 Reduced 27.82%	170,211 $3.94 Million
Q4 2022 Feb 10, 2023	SELL	$18.63 - $27.35 $958,848 - $1.41 Million	-51,468 Reduced 17.92%	235,816 $6.18 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $2.91 Million - $3.89 Million	166,342 Added 137.54%	287,284 $5.65 Million
Q2 2022 Aug 05, 2022	BUY	$12.59 - $18.8 $1.19 Million - $1.78 Million	94,795 Added 362.55%	120,942 $2.12 Million
Q1 2022 May 12, 2022	BUY	$12.02 - $16.69 $70,689 - $98,153	5,881 Added 29.02%	26,147 $428,000
Q4 2021 Feb 10, 2022	BUY	$10.69 - $16.83 $216,643 - $341,076	20,266 New	20,266 $331,000

Others Institutions Holding KDNY

# of Institutions

Shares Held

234K

Call Options Held

Put Options Held

View Full List

About CHINOOK THERAPEUTICS, INC.

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

More about KDNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account